Magram has over 20 years of drug discovery and development experience. She was the founding chief scientific officer of Northern Biologics, a Toronto Canada based biotechnology company. Prior to Northern Biologics, she served as the site head for Pfizer's Centers for Therapeutic Innovation, New York.
Previously, Magram was vice president, immunology and inflammation research at Boehringer Ingelheim, overseeing a department committed to drug discovery to address unmet medical needs in autoimmune disease.
Prior to Boehringer Ingelheim, she was an associate director of G protein-coupled receptor drug discovery at OSI Pharmaceuticals. She also previously spent over five years at Hoffmann-La Roche focused on using model systems to understand the pathophysiology of disease and to identify new therapies.
Magram completed her postdoctoral training in the laboratory of Nobel Laureate J. Michael Bishop, M.D. at the University of California, San Francisco School of Medicine and obtained her Ph.D. in the laboratory of Franklin Costantini, Ph.D. in the Department of Genetics and Development at Columbia University Irving Medical Center.
Privately held Quentis Therapeutics is pursuing first-in-class endoplasmic reticulum stress response-targeted therapies to address serious diseases such as cancer.
The company is pioneering the use of ER stress response modulators to boost the immune system's ability to fight cancer and to help more cancer patients benefit from immunotherapy. Its lead program is a first-in-class, small molecule, IRE1α inhibitor.
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP